BioLineRx Ltd. (BLRX) Is A Stock You Should Watch

Business man trader investor analyst using mobile phone app analytics for cryptocurrency financial stock market analysis analyze graph trading data index investment growth chart on smartphone screen.

As of Wednesday close, BioLineRx Ltd.’s (NASDAQ:BLRX) stock traded at $0.69. The average number of shares traded per day over the past five days has been 287,000 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0199 gain in that time frame. In the last twenty days, the average volume was 522,295, while in the previous 50 days, it was 425,648.

Since last month, BLRX stock retreated -17.29%. Shares of the company fell to $0.5700 on 11/11/22, the lowest level in the past month. A 52-week high of $3.02 was reached on 01/18/22 after having rallying from a 52-week low of $0.57. Since the beginning of this year, BLRX’s stock price has dropped by -66.18% or -$1.3501, and marked a new high 3 times. However, the stock has declined by -77.16% since its 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Financial Health

In the three months ended June 29, BioLineRx Ltd.’s quick ratio stood at 4.60, while its current ratio was 4.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.03, and the total debt-to-equity ratio was 0.03. Based on annual data, BLRX earned $1.01 million in gross profit and brought in $24.78 million in revenue.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected BioLineRx Ltd. to report -$0.11 quarterly earnings, the actual figure was -$0.15 per share, beating the consensus estimate by -36.40%. During the quarter, the company generated -$6.92 million in EBITDA. The liabilities of BioLineRx Ltd. were 26.15 million at the end of its most recent quarter ended June 29, and its total debt was $2.61 million.

Technical Picture

This quick technical analysis looks at BioLineRx Ltd.’s (BLRX) price momentum. With a historical volatility rate of 72.61%, the RSI 9-day stood at 41.37% on 23 November.

With respect to its five-day moving average, the current BioLineRx Ltd. price is up by +2.97% percent or $0.0199. At present, BLRX shares trade -17.87% below its 20-day simple moving average and -46.93% percent below its 100-day simple moving average. However, the stock is currently trading approximately -55.20% below its SMA50 and -61.46% below its SMA200.

Stochastic coefficient K was 35.80% and Stochastic coefficient D was 33.50%, while ATR was 0.0650. Given the Stochastic reading of 38.68% for the 14-day period, the RSI (14) reading has been calculated as 38.82%.

Analyst Ratings

Maxim Group upgraded its rating on BioLineRx Ltd. (NASDAQ: BLRX) to a Buy in a note to investors on May 18, 2017. The analysts firm previously had a Hold rating on the stock.BioLineRx Ltd. (BLRX) has been rated Buy by analysts. According to 0 brokerage firms, BLRX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate BioLineRx Ltd. stock as buy, with 2 recommending it as overweight.

With a median target price of $6.00, the current consensus forecast for the stock is $4.00 – $19.00. Based on these forecasts, analysts predict BioLineRx Ltd. (BLRX) will achieve an average price target of $9.67.


Please enter your comment!
Please enter your name here